Imbruvica (ibrutinib)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) June 2016 ADVERSE REACTIONS Postmarketing Experience (Addition) Respiratory disorders: interstitial lung disease (includes...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts